As a global leader in skin health, there’s always something new at Stiefel, a GSK company.
- Follow Us:
-
-
-
-
If you are a member of the press, please contact:
GSK Media Relations
+ 44 (0)20 8047 5502
Stiefel, a GSK company, works with the CSDF based on a common goal of improving the quality of life for those affected by skin conditions. Learn more about Stiefel's work with CSDF
Learn about our newest innovative technologies and find out who to contact with media requests.
March 4, 2013
Regulatory Update – Stiefel, a GSK company announces a new, alternate, fixed-dose combination of Duac® (clindamycin 1% and benzoyl peroxide 3%) gains positive recommendation for approval in Europe
View Press ReleaseOctober 15, 2012
GSK Announces that Stiefel Plant in Sligo will Remain OpenView Press Release
September 27, 2012
Stiefel receives US FDA approval of Sorilux™ Foam, 0.005% for topical treatment of plaque psoriasis of the scalpView Press Release
June 11, 2012
Stiefel signs worldwide acquisition and license agreement for Toctino®View Press Release
May 30, 2012
Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitisView Press Release
May 11, 2012
Stiefel receives US FDA approval of Fabior™ Foam, 0.1%View Press Release
March 16, 2012
Stiefel and ILDS Announce Completion of First Year of Hats on for Skin Health CampaignView Press Release
November 8, 2011
New Anti-Aging Treatment Provides Increased Hydration and Skin Firmness for Consumers of All Ages.View Press Release
August 3, 2011
Regulatory update – Stiefel, A GSK company, files NDA for tazarotene foam.View Press Release
August 1, 2011
One of Nature’s Most-Potent Antioxidants Now Available in A New Anti-Aging Treatment.View Press Release
